Home > Insider Trading > Filing (0001209191-21-021828)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1490978	Schrodinger Inc.	SDGR	Pharmaceutical Preparations (2834)	954284541

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1797782	Jorg Weiser	C/O Schrodinger, Inc., 120 West 45Th Street, 17Th Floor New York NY 10036	Evp & Managing Director	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-16	18,095	$3.07	181,511	No	4	M	Direct
Common Stock	Disposition	2021-03-16	18,095	$82.00	163,416	No	4	S	Direct
Common Stock	Acquisiton	2021-03-16	6,527	$4.34	169,943	No	4	M	Direct
Common Stock	Disposition	2021-03-16	6,527	$82.00	163,416	No	4	S	Direct
Common Stock	Disposition	2021-03-16	37,060	$82.00	126,356	No	4	S	Direct
Common Stock	Disposition	2021-03-17	6,600	$78.07	119,756	No	4	S	Direct
Common Stock	Disposition	2021-03-17	1,500	$79.70	118,256	No	4	S	Direct
Common Stock	Disposition	2021-03-17	904	$80.85	117,352	No	4	S	Direct
Common Stock	Disposition	2021-03-17	300	$81.33	117,052	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-03-16	18,095	$0.00	18,095	$3.07
Common Stock	Stock Option (right to buy)	Disposition	2021-03-16	6,527	$0.00	6,527	$4.34

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2026-05-10	No	4	M	Direct
9,614		2028-11-29	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	17,390	Indirect	BY ANTERIO CONSULT AND RESEARCH GMBH

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.73 to $78.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.25 to $80.18, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.32 to $81.31, inclusive.
The shares are beneficially owned by Anterio Consult & Research GmbH ("Anterio"). Dr. Weiser is a shareholder and former managing director of Anterio and disclaims beneficial ownership of the shares held by Anterio, except to the extent of his pecuniary interest therein, if any.
The option was granted on May 11, 2016 and is fully vested.
This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.